NEW
Takhzyro

Takhzyro

Manufacturer:

Takeda

Distributor:

Zuellig
/
Firma Chun Cheong
Concise Prescribing Info
Contents
Lanadelumab
Indications/Uses
Routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients ≥12 yr.
Dosage/Direction for Use
SC Initially 300 mg every 2 wk. Consider dose reduction of 300 mg every 4 wk in patients who are stably attack-free on treatment, especially those w/ low wt.
Contraindications
Special Precautions
Discontinue immediately & initiate appropriate treatment in case of a severe hypersensitivity reaction. Not intended for treatment of acute HAE attacks. Interference w/ activated partial thromboplastin time assay. Preferable to avoid during pregnancy. Lactation. Safety & efficacy have not been established in childn <12 yr.
Adverse Reactions
Inj site reactions. Hypersensitivity; dizziness; rash maculo-papular; myalgia; increased ALT & AST.
Drug Interactions
Additive effect w/ rescue medication C1 esterase inhibitor.
MIMS Class
Other Cardiovascular Drugs
ATC Classification
B06AC05 - lanadelumab ; Belong to the class of drugs used in the treatment of hereditary angioedema.
Presentation/Packing
Form
Takhzyro soln for inj 300 mg/2 mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in